This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Context. AZ13824374 (AstraZeneca) is an in vitro ATAD2 inhibitor. Reviewer and nominator Julien Lefranc says, “several ATAD2 probes have been…
molecule
1 year ago ●
2 mins read
Context. ASP5878 (Astellas Pharma Inc.) is an oral pan-FGFR inhibitor. The four FGFRs have emerged as attractive targets for cancer…
molecule
1 year ago ●
2 mins read
Context. AZD7648 (AstraZeneca) is an oral DNA-PK inhibitor. DNA-PK, ATR, and ATM are all kinases involved in DNA damage repair…
molecule
1 year ago ●
2 mins read
Context. T-690 (Takeda) is an oral GCS inhibitor that is brain-penetrant, non-basic, and non-competitive with UDP-glucose. We recently highlighted a…
molecule
1 year ago ●
3 mins read
Context. MAP855 (Novartis Institutes for BioMedical Research) is an oral MEK1/2 active-site inhibitor. Several MEK inhibitors (e.g. cobimetinib, trametinib) have…
molecule
1 year ago ●
2 mins read
S-217622 is the first oral, non-covalent, non-peptidic SARS-CoV-2 3CL (main protease) inhibitor clinical candidate, currently in Ph. II/III trials as…
molecule
1 year ago ●
1 min read
Load More
